Epidermal growth factor receptor targeted doxorubicin and vitexin loaded niosomes for enhanced breast cancer therapy

Author:

Malathi S.1,Sisila Valappil2,Singaravel V.3,Venkatesan Nandakumar45,Pakrudheen Iqbal67,Dhanaraj R.3,Ayyadurai Niraikulam2,Bhuvarahamurthy V.3,Kalkura S. Narayana1ORCID

Affiliation:

1. Crystal Growth Centre, Anna University, Guindy, Chennai 600025, India

2. Biochemistry & Biotechnology, CSIR-Central Leather Research Institute, Adyar, Chennai 600020, India

3. Department of Medical Biochemistry, Post-graduate Institute of Basic Medical Sciences, University of Madras, Taramani, Chennai 600113, India

4. Department of Pediatrics, Obstetrics, and Gynaecology, University of Valencia, Valencia, 46010, Spain

5. Sri Ramachandra Faculty of Engineering and Technology, Sri Ramachandra Institute of Higher Education and Research, Chennai 600116, India

6. Department of Chemistry, CMR Institute of Technology, Bengaluru 560037, India

7. Centre of Excellence- Sensors & Nanoelectronics, CMR Institute of Technology, Bengaluru 560037, India

Abstract

NIODVC (cetuximab-conjugated doxorubicin and vitexin loaded niosome) proves effective for targeted breast cancer therapy. Enhanced cytotoxicity, cellular uptake, and gene downregulation show promise.

Funder

University Grants Commission

University of Madras

Council of Scientific and Industrial Research, India

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science,Chemistry (miscellaneous)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3